SALT LAKE CITY | July 9, 2026
Sera Prognostics Inc., a leader in precision pregnancy diagnostics, has announced the publication of a new subgroup analysis from its PRIME randomized controlled trial, demonstrating that PreTRM® Test-guided care significantly improves neonatal outcomes in first-time pregnancies. Published in The Journal of Maternal-Fetal & Neonatal Medicine, the analysis showed a 22% reduction in neonatal intensive care unit (NICU) admissions among women receiving biomarker-guided care compared with routine pregnancy management. The study further demonstrated improved newborn health, enhanced screening efficiency, and the potential to reduce healthcare costs in one of the largest underserved maternal populations. With approximately 40% of births in the United States occurring in first-time mothers, the findings highlight the clinical value of early biomarker-based risk assessment in pregnancies where traditional obstetric history is unavailable. The results strengthen the growing evidence supporting PreTRM® as an innovative blood-based test capable of enabling earlier intervention to reduce the burden of preterm birth, improve neonatal outcomes, and support more personalized prenatal care.
PRIME Study Demonstrates Significant Improvement in Neonatal Outcomes
The newly published subgroup analysis evaluated 1,783 nulliparous women participating in the PRIME randomized controlled trial, focusing specifically on first-time pregnancies that traditionally present significant challenges for clinicians due to the absence of prior pregnancy history. Women receiving PreTRM® Test-guided care, combined with evidence-based interventions including progesterone therapy, low-dose aspirin, and specialized care management, experienced a 22% overall relative reduction in NICU admissions compared with routine care.
Among infants born following spontaneous preterm birth, NICU admissions were reduced by approximately two-fold. The study also demonstrated a 30% reduction in severe composite neonatal morbidity, with rates decreasing from 9.1% in the control group to 6.4% among patients receiving biomarker-guided care. Researchers reported that only 28 first-time pregnancies needed to be screened and treated to prevent one NICU admission, highlighting the strong clinical efficiency of the screening strategy while demonstrating that the interventions were safe, well tolerated, and clinically effective.
Early Risk Prediction Supports Better Pregnancy Management
Advertisement
Unlike conventional risk assessment methods that rely heavily on previous pregnancy outcomes, the PreTRM® Test provides physicians with an individualized blood-based biomarker assessment capable of identifying women at increased risk for spontaneous preterm birth between 18 and 20 weeks of pregnancy. This early identification enables healthcare providers to implement proactive interventions before complications develop, creating opportunities to improve maternal and neonatal outcomes. Preterm birth remains the leading cause of illness and death among newborns and continues to represent a significant public health challenge.
According to the latest national data, the United States has received a D+ grade for preterm birth for four consecutive years, emphasizing the urgent need for improved screening strategies capable of identifying high-risk pregnancies earlier. The findings suggest that integrating biomarker-guided precision medicine into routine prenatal care could substantially improve risk stratification for first-time mothers while reducing preventable complications associated with premature delivery.
Precision Pregnancy Care Could Improve Outcomes and Reduce Costs
The latest PRIME findings further reinforce Sera Prognostics’ leadership in precision pregnancy diagnostics, supporting broader adoption of PreTRM® Test-guided care across diverse clinical settings. Beyond improving newborn health, reducing NICU admissions carries significant economic implications because neonatal intensive care represents one of the most expensive components of maternal and newborn healthcare. Earlier identification of high-risk pregnancies may therefore generate meaningful cost savings for healthcare systems while improving long-term outcomes for infants and families. Sera Prognostics continues expanding the clinical evidence supporting its precision medicine platform, which combines innovative pregnancy biomarkers with personalized clinical decision-making to enable earlier intervention before complications occur.
As demand grows for predictive maternal health technologies capable of reducing preterm birth and improving neonatal outcomes, the latest publication strengthens the scientific foundation for incorporating PreTRM® into routine obstetric practice, positioning the company at the forefront of advancing maternal-fetal medicine, pregnancy diagnostics, and precision prenatal healthcare.
Source: Sera Prognostics press release
